Compare iShares MSCI Indonesia ETF (EIDO) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Koninklijke Philips NV — how do they compare? iShares MSCI Indonesia ETF trades at $12.2, while Koninklijke Philips NV trades at $27.23 (market cap $26.29B). The key difference: Koninklijke Philips NV pays a 3.75% dividend while iShares MSCI Indonesia ETF pays none, and Koninklijke Philips NV is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.
| EIDO | PHG | |
|---|---|---|
52-Week High | $19.22 | $32.91 |
52-Week Low | $10.80 | $24.38 |
Market Cap | — | $26.29B |
Sector | — | Health |
Enterprise Value | — | $32.56B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Indonesia ETF (EIDO) trades at $12.20, up 1.08% on the day, while technical indicators signal a bearish trend with moving averages and overall signals in sell territory. Recent news highlights Indonesia's economic initiatives, including a $15 billion AI-integrated free-meal program and central bank rate hikes to support the rupiah, which directly impacts this country-focused ETF. The fund's dividend was reported to have dropped 27% in 2025, raising questions about underlying asset performance.
The outlook for EIDO is tied to Indonesia's macroeconomic stability and government policy execution. Investment opportunity lies in exposure to Indonesia's growth initiatives, but risks include currency volatility from Bank Indonesia's defensive actions, geopolitical pressures on emerging markets, and the ETF's high-yield but potentially unstable dividend profile.
Royal Philips (PHG) trades at $26.06, down 4.68% today, with bearish technical signals but improving fundamentals. The company reported strong Q1 2026 earnings beat and maintains a 5.5% net income margin. Recent FDA clearances for AI-powered medical devices and strategic healthcare partnerships highlight innovation momentum. Cash flow remains positive at $403M for 2025, though debt-to-asset ratio increased to 25.44%.
PHG shows recovery potential with earnings growth and AI healthcare adoption, but faces execution risks and technical weakness. Analyst consensus leans Hold (59%) with no Sell ratings, suggesting cautious optimism. Key risks include competitive pressures and macroeconomic volatility affecting medical equipment demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
